期刊文献+

西咪替丁与兰索拉唑治疗消化性溃疡出血有效性和安全性分析 被引量:6

Efficacy and safety of cimetidine and lansoprazole treat for peptic ulcer bleeding
暂未订购
导出
摘要 目的分析西咪替丁与兰索拉唑治疗消化性溃疡出血的有效性和安全性。方法所有患者均实施对症支持治疗,并选择40例患者使用西咪替丁治疗,与40例使用兰索拉唑治疗的患者比较两组胃液pH值、确定停止出血时间和疼痛消失时间,比较两组发生的并发症和统计两组的临床疗效。结果西咪替丁组治疗后胃内pH值显著低于兰索拉唑组(P<0.05);而凝血时间和疼痛消失时间均显著长于兰索拉唑组(P<0.05);西咪替丁组发生肝肾功能受损和皮疹的比率分别为22.5%和20.0%,均显著高于兰索拉唑组2.5%(P<0.05);西咪替丁组显效率高于兰索拉唑组(P<0.05)。结论兰索拉唑治疗消化性溃疡出血起效快,维持时间长,不良反应少,是一种值得临床推广的方法。 Objective To analyze the efficacy and safety of cimetidine and lansoprazole treat for peptic ulcer bleeding.Methods All patients were implemented of symptomatic and supportive,and 40 cases used cimetidine,anther 40 cases used lansoprazole,compared gastric pH,bleeding time and the pain disappeared time of the two groups,and then compared the complications and clinical efficacy.Results Intragastric pH of cimetidine treatment was significantly lower than lansoprazole group (P 0.05);clotting time and the pain disappeared time of cimetidine treatment were significantly longer than lansoprazole group(P 0.05);the ratio of liver and kidney dysfunction of cimetidine treatment were 22.5% and 20.0% and they were significantly higher than lansoprazole group' 2.5% (P 0.05);apparent efficiency of cimetidine treatment was high than lansoprazole group(P 0.05).Conclusion Lansoprazole treatment for peptic ulcer bleeding can quickly stop the bleeding and maintenance of a long time,as well as fewer adverse reactions,so it is worthy of clinical promotion.
出处 《中国医药科学》 2012年第20期45-46,54,共3页 China Medicine And Pharmacy
关键词 西咪替丁 兰索拉唑 消化性溃疡出血 有效性 安全性 Cimetidine Lansoprazole Peptic ulcer bleeding Effectiveness Security
  • 相关文献

参考文献7

二级参考文献31

  • 1李兆申.重视急性非静脉曲张性上消化道出血的规范化诊治[J].中华内科杂志,2005,40(1):3-4. 被引量:81
  • 2白歌,胡伏莲,陆达海,秦晶.奥美拉唑静脉注射治疗消化性溃疡和急性胃粘膜病变所致上消化道出血[J].中国临床药理学杂志,1995,11(4):206-209. 被引量:17
  • 3王驰.消化性溃疡并发症的诊断与治疗[J].中国社区医师,2006,22(8):14-15. 被引量:4
  • 4无,许国铭(整理),邹多武(整理).中国消化性溃疡治疗现状调查报告[J].中华消化杂志,2007,27(2):114-117. 被引量:116
  • 5Bustamante M, Stollman N. The efficacy of proton pump inhibitors in acute ulcer bleeding: a qualitative review. J Clin Gastroenterol, 2000, 30:7-13.
  • 6Freston JW, Pilmer BL, Chiu YL, et al. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. Aliment Pharmacol Ther, 2004,19:1111-1122.
  • 7Freston JW. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. Am J Med, 2004, 117(suppl 5A) : 14S-22S.
  • 8Metz DC, Amer F, Hunt B, et al. Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. Aliment Pharmaeol Ther, 2006, 23: 985-995.
  • 9Forbes GM, Glaser ME, Cullen D J, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up [ J ]. Lancet, 1994,343 (8892) :258-260.
  • 10Parent K. Acid reduction in peptic ulcer disease. Choosing therapy according to drug interactions, individual response, and cost [ J ]. Postgrad Med, 1994,96(6) :53-59.

共引文献83

同被引文献26

引证文献6

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部